---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107898"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:35:51.893879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical eliminates $32M debt, gets FDA approval to expand cochlear implant trial

## Summary
- Extinguished over $32 million in debt, strengthening balance sheet without equity issuance.
- Post-quarter: FDA approved expansion of pivotal clinical trial to final stage; three patients enrolled.
- Closed up to $16 million registered direct offering priced at-the-market under Nasdaq rules.
- Q3 net revenue $42,000; R&D expenses $2.7M; cash $3.556M as of Sept. 30, 2025.
- Expanded global patent portfolio with four new patents in U.S., Europe, and Australia.

## SEC filing metadata
- accession: 0001213900-25-107898
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/0001213900-25-107898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025107898/ea0264709-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107898
- JSON: https://secwatch.observer/filing/0001213900-25-107898.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.